Upstream Bio, Inc (UPB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Upstream Bio, Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Upstream Bio, Inc (UPB) has returned -66.85% so far this year and 47.06% over the past 12 months.

Based on dividend-adjusted daily data since Oct 11, 2024, UPB's average daily return is -0.04%, while the average monthly return is +1.27%. At this rate, your investment would double in approximately 4.6 years.

Historically, 56% of months were positive and 44% were negative. The best month was Apr 2025 with a return of +51.3%, while the worst month was Feb 2026 at -75.3%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.

On a daily basis, UPB closed higher 50% of trading days. The best single day was Sep 2, 2025 with a return of +18.3%, while the worst single day was Feb 11, 2026 at -47.2%.

Upstream Bio, Inc has an annualized alpha of -19.44%, beta of 1.21, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since October 14, 2024.

• This stock participated in 372.02% of S&P 500 Index downside but only 309.48% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

UPB ranks 58 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Upstream Bio, Inc (UPB) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Upstream Bio, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Upstream Bio, Inc was 77.84%, occurring on Apr 8, 2025. Recovery took 160 trading sessions.

The current Upstream Bio, Inc drawdown is 72.39%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Upstream Bio, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Upstream Bio, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.